$CHE
CHEMED CORP

2024 Q1 Form 10-K Financial Statement

#000156276224000045 Filed on February 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $589.2M $585.9M $2.264B
YoY Change 5.19% 7.18% 6.06%
Cost Of Revenue $385.1M $358.3M $1.466B
YoY Change 3.89% 2.51% 6.99%
Gross Profit $204.1M $227.6M $798.8M
YoY Change 7.73% 15.47% 4.41%
Gross Profit Margin 34.64% 38.84% 35.28%
Selling, General & Admin $115.9M $95.60M $395.1M
YoY Change 15.76% 4.17% 10.15%
% of Gross Profit 56.77% 42.01% 49.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $15.81M $15.54M $60.87M
YoY Change 6.82% 6.37% 2.86%
% of Gross Profit 7.74% 6.83% 7.62%
Operating Expenses $115.9M $111.3M $395.1M
YoY Change 15.76% 0.66% 10.15%
Operating Profit $72.33M $116.2M $340.6M
YoY Change -0.67% 34.4% -0.85%
Interest Expense $425.0K $3.065M $3.108M
YoY Change -72.6% -299.8% -32.2%
% of Operating Profit 0.59% 2.64% 0.91%
Other Income/Expense, Net $12.58M $171.0K $12.91M
YoY Change -12310.68% -55.12% -239.78%
Pretax Income $84.49M $115.6M $350.4M
YoY Change 18.72% 40.28% 6.28%
Income Tax $19.47M $25.54M $77.86M
% Of Pretax Income 23.04% 22.09% 22.22%
Net Earnings $65.02M $90.05M $272.5M
YoY Change 20.13% 44.95% 9.17%
Net Earnings / Revenue 11.03% 15.37% 12.03%
Basic Earnings Per Share $4.30 $18.11
Diluted Earnings Per Share $4.24 $5.90 $17.93
COMMON SHARES
Basic Shares Outstanding 15.12M 15.05M
Diluted Shares Outstanding 15.34M 15.20M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $313.4M $264.0M $264.0M
YoY Change 439.76% 256.09% 256.09%
Cash & Equivalents $313.4M $264.0M $264.0M
Short-Term Investments
Other Short-Term Assets $38.22M $43.37M $43.37M
YoY Change -3.7% -11.14% -11.14%
Inventory $10.71M $12.00M $12.00M
Prepaid Expenses
Receivables $177.3M $181.5M $181.5M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $539.6M $500.8M $500.8M
YoY Change 105.79% 83.72% 83.72%
LONG-TERM ASSETS
Property, Plant & Equipment $202.8M $203.8M $330.2M
YoY Change -0.68% 2.07% -1.54%
Goodwill $591.5M $585.0M
YoY Change 1.76% 0.64%
Intangibles $88.14M $90.26M
YoY Change -9.46% -9.49%
Long-Term Investments $117.6M $106.1M $106.1M
YoY Change 20.74% 13.87% 13.87%
Other Assets $56.18M $55.62M $53.96M
YoY Change -2.32% -7.0% -9.78%
Total Long-Term Assets $1.188B $1.167B $1.167B
YoY Change 1.63% -0.18% -0.18%
TOTAL ASSETS
Total Short-Term Assets $539.6M $500.8M $500.8M
Total Long-Term Assets $1.188B $1.167B $1.167B
Total Assets $1.728B $1.668B $1.668B
YoY Change 20.71% 15.68% 15.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $56.20M $64.03M $48.33M
YoY Change 39.53% 52.88% 15.4%
Accrued Expenses $158.3M $195.9M $195.9M
YoY Change 0.42% 3.5% 3.5%
Deferred Revenue
YoY Change
Short-Term Debt $13.60M $15.70M $15.70M
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Short-Term Liabilities $282.0M $312.1M $312.1M
YoY Change -0.52% 4.99% 4.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $12.85M $13.00M $217.8M
YoY Change 2.77% 7.14% 1.33%
Total Long-Term Liabilities $12.85M $13.00M $217.8M
YoY Change -55.3% -87.57% -29.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $282.0M $312.1M $312.1M
Total Long-Term Liabilities $12.85M $13.00M $217.8M
Total Liabilities $544.1M $560.2M $560.2M
YoY Change -1.27% -12.91% -12.91%
SHAREHOLDERS EQUITY
Retained Earnings $2.506B $2.447B
YoY Change 11.55% 11.33%
Common Stock $1.436B $1.378B
YoY Change 17.42% 16.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.761B $2.720B
YoY Change 6.52% 5.08%
Treasury Stock Shares
Shareholders Equity $1.183B $1.108B $1.108B
YoY Change
Total Liabilities & Shareholders Equity $1.728B $1.668B $1.668B
YoY Change 20.71% 15.68% 15.68%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $65.02M $90.05M $272.5M
YoY Change 20.13% 44.95% 9.17%
Depreciation, Depletion And Amortization $15.81M $15.54M $60.87M
YoY Change 6.82% 6.37% 2.86%
Cash From Operating Activities $84.55M $108.6M $330.3M
YoY Change 39.77% 8.35% 6.59%
INVESTING ACTIVITIES
Capital Expenditures $12.16M $11.78M $56.85M
YoY Change -28.54% -35.49% -0.82%
Acquisitions $7.300M $3.994M
YoY Change 13.18%
Other Investing Activities $8.000K $109.0K $434.0K
YoY Change -94.24% -108.87% -50.57%
Cash From Investing Activities -$19.39M -$11.67M -$60.64M
YoY Change 13.94% -40.12% 2.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $67.70M
YoY Change -40.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.77M -6.085M -79.83M
YoY Change -73.52% -57.64% -61.85%
NET CHANGE
Cash From Operating Activities 84.55M 108.6M 330.3M
Cash From Investing Activities -19.39M -11.67M -60.64M
Cash From Financing Activities -15.77M -6.085M -79.83M
Net Change In Cash 49.39M 90.81M 189.8M
YoY Change -407.32% 36.87% 360.41%
FREE CASH FLOW
Cash From Operating Activities $84.55M $108.6M $330.3M
Capital Expenditures $12.16M $11.78M $56.85M
Free Cash Flow $72.39M $96.78M $273.4M
YoY Change 66.51% 18.12% 8.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 che Stock Options Forfeiture Rate
StockOptionsForfeitureRate
CY2022 che Stock Options Forfeiture Rate
StockOptionsForfeitureRate
CY2023 che Stock Options Forfeiture Rate
StockOptionsForfeitureRate
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000019584
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
1-8351
CY2023 dei Entity Registrant Name
EntityRegistrantName
CHEMED CORPORATION
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 2600
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
255 East Fifth Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Cincinnati
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-0791746
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
45202-4726
CY2023 dei City Area Code
CityAreaCode
513
CY2023 dei Local Phone Number
LocalPhoneNumber
762-6690
CY2023 dei Security12b Title
Security12bTitle
Capital Stock – Par Value $1 Per Share
CY2023 dei Trading Symbol
TradingSymbol
CHE
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
8049913329
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15117093
CY2023 dei Auditor Firm
AuditorFirmId
238
CY2023 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2023 dei Auditor Location
AuditorLocation
Cincinnati, Ohio
CY2023 us-gaap Revenues
Revenues
2264417000
CY2022 us-gaap Revenues
Revenues
2134963000
CY2021 us-gaap Revenues
Revenues
2139261000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1465602000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1369877000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1369458000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
395120000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
358727000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
366727000
CY2023 us-gaap Depreciation
Depreciation
50802000
CY2022 us-gaap Depreciation
Depreciation
49102000
CY2021 us-gaap Depreciation
Depreciation
49011000
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
10063000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
10070000
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
10040000
CY2023 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2261000
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-3691000
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-987000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
1923848000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
1791467000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
1796223000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
340569000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
343496000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
343038000
CY2023 us-gaap Interest Expense
InterestExpense
3108000
CY2022 us-gaap Interest Expense
InterestExpense
4584000
CY2021 us-gaap Interest Expense
InterestExpense
1868000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12906000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9233000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9144000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
350367000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
329679000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
350314000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77858000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80055000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81764000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
272509000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
249624000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
268550000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.11
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
16.72
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
17.14
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15050000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14929000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15671000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
17.93
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
16.53
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
16.85
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15200000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15099000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15938000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263958000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74126000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
181511000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
139408000
CY2023Q4 us-gaap Inventory Net
InventoryNet
12004000
CY2022Q4 us-gaap Inventory Net
InventoryNet
10272000
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
13166000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
18515000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30204000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30291000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
500843000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
272612000
CY2023Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
106126000
CY2022Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
93196000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
203840000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
199714000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
126387000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
135662000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
90264000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
99726000
CY2023Q4 us-gaap Goodwill
Goodwill
585017000
CY2022Q4 us-gaap Goodwill
Goodwill
581295000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55618000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59807000
CY2023Q4 us-gaap Assets
Assets
1668095000
CY2022Q4 us-gaap Assets
Assets
1442012000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
64034000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
41884000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5000000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
6858000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
58568000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
58515000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
88381000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
87350000
CY2023Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
6386000
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
4456000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38635000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38996000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
49188000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
61004000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
312050000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
297205000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
30321000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
38613000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
92500000
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
104069000
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
92330000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100776000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
110513000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13003000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12136000
CY2023Q4 us-gaap Liabilities
Liabilities
560219000
CY2022Q4 us-gaap Liabilities
Liabilities
643297000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37183681
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36795792
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
37184000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36796000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1341273000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1149899000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2446925000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2197918000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
22148927
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
21920993
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2719588000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2588145000
CY2023Q4 che Deferred Compensation Payable In Company Stock
DeferredCompensationPayableInCompanyStock
2082000
CY2022Q4 che Deferred Compensation Payable In Company Stock
DeferredCompensationPayableInCompanyStock
2247000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1107876000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
798715000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1668095000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1442012000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
272509000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
249624000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
268550000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60865000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59172000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59051000
CY2023 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
30082000
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
26254000
CY2021 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
22502000
CY2022 che Deferred Payroll Taxes
DeferredPayrollTaxes
-18175000
CY2021 che Deferred Payroll Taxes
DeferredPayrollTaxes
-18175000
CY2023 us-gaap Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash
PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
9267000
CY2022 us-gaap Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash
PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
6188000
CY2021 us-gaap Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash
PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
7745000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8027000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
14827000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2400000
CY2023 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
2050000
CY2022 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
4000000
CY2021 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
9440000
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1444000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1170000
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1173000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
580000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
342000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
306000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
41488000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2414000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8431000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1732000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
162000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3014000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-87000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2397000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6511000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9348000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
15343000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9832000
CY2023 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
11748000
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-996000
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-20401000
CY2023 che Increase Decrease In Lease Assets And Liabilities
IncreaseDecreaseInLeaseAssetsAndLiabilities
1424000
CY2022 che Increase Decrease In Lease Assets And Liabilities
IncreaseDecreaseInLeaseAssetsAndLiabilities
-1471000
CY2021 che Increase Decrease In Lease Assets And Liabilities
IncreaseDecreaseInLeaseAssetsAndLiabilities
44000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9952000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
45779000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10305000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
12802000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3350000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
12074000
CY2023 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
836000
CY2022 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-26000
CY2021 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1285000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
330299000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
309886000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
308597000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56854000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57325000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58675000
CY2023 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
3994000
CY2022 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
3529000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
640000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2330000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
904000
CY2023 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
434000
CY2022 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
878000
CY2021 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-14000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60642000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59402000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57757000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
102192000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44968000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35848000
CY2023 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
97500000
CY2022 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
2500000
CY2022 us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
100000000
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
67697000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
114515000
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
576042000
CY2023 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
23502000
CY2022 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22017000
CY2021 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22016000
CY2023 us-gaap Increase Decrease In Outstanding Checks Financing Activities
IncreaseDecreaseInOutstandingChecksFinancingActivities
15749000
CY2022 us-gaap Increase Decrease In Outstanding Checks Financing Activities
IncreaseDecreaseInOutstandingChecksFinancingActivities
-11884000
CY2021 us-gaap Increase Decrease In Outstanding Checks Financing Activities
IncreaseDecreaseInOutstandingChecksFinancingActivities
11884000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9557000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15611000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15129000
CY2022 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
306800000
CY2021 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
25300000
CY2022 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
121800000
CY2021 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
210300000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1586000
CY2023 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
490000
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1108000
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-165000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-79825000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-209253000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-380620000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
189832000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
41231000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-129780000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74126000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32895000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162675000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263958000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74126000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32895000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
901200000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
268550000
CY2021 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
1.40
CY2021 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
22016000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
52139000
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
576483000
CY2021 us-gaap Stockholders Equity Other
StockholdersEquityOther
-117000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
623273000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
249624000
CY2022 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
1.48
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
22017000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
62969000
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
114074000
CY2022 us-gaap Stockholders Equity Other
StockholdersEquityOther
-1060000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
798715000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
272509000
CY2023 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
1.56
CY2023 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
23502000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
133427000
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
73813000
CY2023 us-gaap Stockholders Equity Other
StockholdersEquityOther
540000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1107876000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">NATURE OF OPERATIONS</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.16in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.09in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We operate through our </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">two</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> wholly-owned subsidiaries: VITAS Healthcare Corporation (“VITAS”) and Roto-Rooter Group, Inc. (“Roto-Rooter”). VITAS focuses on hospice care that helps make terminally ill patients' final days as comfortable as possible. Through its team of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter provides plumbing, drain cleaning and water restoration services to both residential and commercial customers. Through its network of company-owned branches, Independent Contractors and franchisees, Roto-Rooter offers plumbing, drain cleaning service and water restoration to over </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the U.S. population.</span></p>
CY2023 che Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
2
CY2023Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
45200000
CY2023 us-gaap Advertising Expense
AdvertisingExpense
72200000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
68600000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
62100000
CY2020 che Deferred Payroll Taxes
DeferredPayrollTaxes
36400000
CY2021 che Deferred Payroll Taxes Paid
DeferredPayrollTaxesPaid
18200000
CY2022 che Deferred Payroll Taxes Paid
DeferredPayrollTaxesPaid
18200000
CY2022Q2 che Percentage Of Sequestration Reimbursement
PercentageOfSequestrationReimbursement
0.01
che Percentage Of Sequestration Reimbursement
PercentageOfSequestrationReimbursement
0.02
CY2021 che Pandemic Expenses Incurred
PandemicExpensesIncurred
14000000.0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">CONCENTRATION OF RISK</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, and 2022, approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">64</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, respectively, of VITAS’ total accounts receivable balances were from Medicare and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, respectively, of VITAS’ total accounts receivable balances were due from various state Medicaid or managed Medicaid programs. Combined accounts receivable from Medicare, Medicaid, and managed Medicaid represent approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">80</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the consolidated net accounts receivable in the accompanying consolidated balance sheets as of December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">VITAS has a pharmacy services contract with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> service provider for specified pharmacy services related to its hospice operations. Similarly, effective January 1, 2022, VITAS obtains the majority of its medical supplies from a single vendor. A large majority of VITAS’ pharmaceutical and medical supplies purchases are from these vendors. The pharmaceutical and medical supplies purchased by VITAS are available through many providers in the United States. However, a disruption from VITAS’ main service providers could adversely impact VITAS’ operations, including temporary logistical challenges and increased cost associated with getting medication and medical supplies to our patients. </span></p>
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
5900000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
9900000
CY2023Q3 che Income Tax Expense Benefit Resulting From Realignment Of State And Local Tax Structure
IncomeTaxExpenseBenefitResultingFromRealignmentOfStateAndLocalTaxStructure
-4200000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
3704000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1403000
CY2021Q4 us-gaap Goodwill
Goodwill
578591000
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
2793000
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-89000
CY2022Q4 us-gaap Goodwill
Goodwill
581295000
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
3682000
CY2023 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
40000
CY2023Q4 us-gaap Goodwill
Goodwill
585017000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
2645000
CY2023 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
up to 5 years
CY2023 us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
options to terminate the lease within 1 year
CY2023 che Historical Claims Data Period Of Time
HistoricalClaimsDataPeriodOfTime
P10Y
CY2023 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
-6862000
CY2022 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
-5790000
CY2021 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
-6332000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.222
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.243
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.233
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
4300000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ESTIMATES </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates</span>
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1348112000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1315065000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1231010000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1201564000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1289433000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1261246000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
97500000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5000000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
92500000
CY2023 che Stock Options Number Of Stock Incentive Plans
StockOptionsNumberOfStockIncentivePlans
4
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6100000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P2Y10M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P2Y10M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P2Y10M24D
CY2023 che Share Based Compensation Arrangement By Share Based Payment Award Expiration Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationYear
2025
CY2022 che Share Based Compensation Arrangement By Share Based Payment Award Expiration Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationYear
2024
CY2021 che Share Based Compensation Arrangement By Share Based Payment Award Expiration Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationYear
2023
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40793000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33613000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31420000
CY2023 che Share Based Compensation Arrangement By Share Based Payment Award Income Tax Benefit Recognized In Income
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncomeTaxBenefitRecognizedInIncome
9709000
CY2022 che Share Based Compensation Arrangement By Share Based Payment Award Income Tax Benefit Recognized In Income
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncomeTaxBenefitRecognizedInIncome
8487000
CY2021 che Share Based Compensation Arrangement By Share Based Payment Award Income Tax Benefit Recognized In Income
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncomeTaxBenefitRecognizedInIncome
7918000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
54681000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
53339000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
62038000
CY2023 che Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalIntrinsicValue
1444000
CY2022 che Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalIntrinsicValue
1170000
CY2021 che Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalIntrinsicValue
1173000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
545.69
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
496.25
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
482.66
CY2023Q4 che Stock Price On Date Of Issuance
StockPriceOnDateOfIssuance
509.46
CY2022Q4 che Stock Price On Date Of Issuance
StockPriceOnDateOfIssuance
462.04
CY2021Q4 che Stock Price On Date Of Issuance
StockPriceOnDateOfIssuance
445.35
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
111.24
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
104.69
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
96.91
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
315555
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
312598
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
326806
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0499
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0439
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0087
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.1924
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.2229
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.2881
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.003
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.003
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.003
CY2023 us-gaap Net Income Loss
NetIncomeLoss
272509000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
249624000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
268550000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
6270000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
355000
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
377000
CY2023 us-gaap Interest Expense
InterestExpense
3108000
CY2022 us-gaap Interest Expense
InterestExpense
4584000
CY2021 us-gaap Interest Expense
InterestExpense
1868000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77858000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80055000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81764000
CY2023Q4 us-gaap Assets
Assets
1668095000
CY2022Q4 us-gaap Assets
Assets
1442012000
CY2021Q4 us-gaap Assets
Assets
1342723000
CY2023 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
61238000
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
61868000
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
58856000
CY2023 che Depreciation Amortization Of Intangibles And Stock Award
DepreciationAmortizationOfIntangiblesAndStockAward
60865000
CY2022 che Depreciation Amortization Of Intangibles And Stock Award
DepreciationAmortizationOfIntangiblesAndStockAward
59172000
CY2021 che Depreciation Amortization Of Intangibles And Stock Award
DepreciationAmortizationOfIntangiblesAndStockAward
59051000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10100000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10100000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10000000.0
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
10049000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
10035000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9688000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
458000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
308000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1768000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
81271000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
48965000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
32306000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
139229000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
48965000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
90264000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
109864000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
67716000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42148000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
167442000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
67716000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
99726000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81764000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
39436000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
38620000
CY2023Q4 che Deferred Tax Assets Tax Deferred Expense Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseLeaseLiabilities
34028000
CY2022Q4 che Deferred Tax Assets Tax Deferred Expense Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseLeaseLiabilities
39057000
CY2023Q4 che Payment Of Liabilities Discounted Operations Year One
PaymentOfLiabilitiesDiscountedOperationsYearOne
826000
CY2023Q4 che Payment Of Liabilities Discounted Operations Year Two
PaymentOfLiabilitiesDiscountedOperationsYearTwo
300000
CY2023Q4 che Payment Of Liabilities Discounted Operations Thereafter
PaymentOfLiabilitiesDiscountedOperationsThereafter
596000
CY2023Q4 che Total Estimated Timing Of Payments Of Liabilities Related To Discontinued Operations
TotalEstimatedTimingOfPaymentsOfLiabilitiesRelatedToDiscontinuedOperations
1722000
CY2023Q4 che Capitalized Property And Equipment Not Paid
CapitalizedPropertyAndEquipmentNotPaid
690000
CY2022Q4 che Capitalized Property And Equipment Not Paid
CapitalizedPropertyAndEquipmentNotPaid
1900000
CY2021Q4 che Capitalized Property And Equipment Not Paid
CapitalizedPropertyAndEquipmentNotPaid
1900000
CY2023Q4 che Cash Overdraft Payable Included In Accounts Payable
CashOverdraftPayableIncludedInAccountsPayable
15700000
CY2022Q4 che Cash Overdraft Payable Included In Accounts Payable
CashOverdraftPayableIncludedInAccountsPayable
0
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9023000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9102000
CY2023Q4 che Deferred Tax Assets Implicit Price Concessions
DeferredTaxAssetsImplicitPriceConcessions
7294000
CY2022Q4 che Deferred Tax Assets Implicit Price Concessions
DeferredTaxAssetsImplicitPriceConcessions
7572000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1652000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1443000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1259000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1330000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
92692000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
97124000
CY2023 che Market Value Gains On Assets Held In Deferred Compensation Trust
MarketValueGainsOnAssetsHeldInDeferredCompensationTrust
6404000
CY2022 che Market Value Gains On Assets Held In Deferred Compensation Trust
MarketValueGainsOnAssetsHeldInDeferredCompensationTrust
-9970000
CY2021 che Market Value Gains On Assets Held In Deferred Compensation Trust
MarketValueGainsOnAssetsHeldInDeferredCompensationTrust
8310000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
6270000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
355000
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
377000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
232000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
382000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
457000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12906000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9233000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9144000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
75333000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
52910000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
64620000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
9983000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
11813000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
14233000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
569000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
505000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
511000
CY2023 che Deferred Federal State And Local Income Tax Expense Benefit
DeferredFederalStateAndLocalIncomeTaxExpenseBenefit
-8029000
CY2022 che Deferred Federal State And Local Income Tax Expense Benefit
DeferredFederalStateAndLocalIncomeTaxExpenseBenefit
14821000
CY2021 che Deferred Federal State And Local Income Tax Expense Benefit
DeferredFederalStateAndLocalIncomeTaxExpenseBenefit
2358000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
2000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
6000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
42000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77858000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80055000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
40747000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
43205000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
32411000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
36519000
CY2023Q4 che Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
30891000
CY2022Q4 che Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
35514000
CY2023Q4 che Deferred Tax Liability Deposit With Oas
DeferredTaxLiabilityDepositWithOas
11413000
CY2022Q4 che Deferred Tax Liability Deposit With Oas
DeferredTaxLiabilityDepositWithOas
12769000
CY2023Q4 us-gaap Deferred Tax Liabilities Regulatory Assets
DeferredTaxLiabilitiesRegulatoryAssets
4272000
CY2022Q4 us-gaap Deferred Tax Liabilities Regulatory Assets
DeferredTaxLiabilitiesRegulatoryAssets
5064000
CY2023Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
2552000
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
2634000
CY2023Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
600000
CY2022Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
102000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
127000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
134000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
123013000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
135737000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
30321000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
38613000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
36000000.0
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
41900000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1313000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1379000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1304000
CY2023 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
355000
CY2022 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
422000
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
258000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
263000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
356000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
333000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1221000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1313000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1379000
CY2023Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
145000
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
112000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
73577000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
69233000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
73566000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2306000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
10207000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
10025000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
6600000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
6958000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
7443000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
4330000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
5928000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
9884000
CY2023 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-295000
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-415000
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
614000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77858000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80055000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81764000
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.222
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.243
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.233
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
73876000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
65894000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
99430000
CY2023Q4 us-gaap Undistributed Earnings Of Domestic Subsidiaries
UndistributedEarningsOfDomesticSubsidiaries
35100000
CY2023Q4 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Domestic Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfDomesticSubsidiaries
8000000.0
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
17.93
CY2022 us-gaap Net Income Loss
NetIncomeLoss
249624000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14929000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
16.72
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
130000
CY2022 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
40000
CY2023Q4 che Oas Receivable
OasReceivable
46968000
CY2022Q4 che Oas Receivable
OasReceivable
50274000
CY2023Q4 us-gaap Cash Surrender Value Of Life Insurance
CashSurrenderValueOfLifeInsurance
3651000
CY2022Q4 us-gaap Cash Surrender Value Of Life Insurance
CashSurrenderValueOfLifeInsurance
3636000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2139000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2368000
CY2023Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1197000
CY2022Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1703000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
1663000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
1826000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55618000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59807000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
558712000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
535634000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
354872000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
335920000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
203840000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
199714000
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
8000000.0
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
8900000
CY2023 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
4500000
CY2022 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
5500000
CY2021 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
5800000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
249624000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15099000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
16.53
CY2021 us-gaap Net Income Loss
NetIncomeLoss
268550000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15671000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
126387000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
135662000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38635000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38996000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100776000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
110513000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
139411000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
149509000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
59769000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
59530000
CY2023 us-gaap Sublease Income
SubleaseIncome
93000
CY2022 us-gaap Sublease Income
SubleaseIncome
181000
CY2023 us-gaap Lease Cost
LeaseCost
59676000
CY2022 us-gaap Lease Cost
LeaseCost
59349000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
49777000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
49571000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
37111000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
57551000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M25D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0309
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
17.14
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
44928000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
37248000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
28897000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16525000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
11285000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10597000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
149480000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10069000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
139411000
CY2023 che Operating Lease Payments Include To Extended Lease Terms
OperatingLeasePaymentsIncludeToExtendedLeaseTerms
3800000
CY2023 che Lessee Operating Lease Lease Signed But Not Yet Commenced Payments
LesseeOperatingLeaseLeaseSignedButNotYetCommencedPayments
740000
CY2023 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
26475000
CY2022 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
11533000
CY2021 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
28554000
CY2023Q4 us-gaap Common Stock Shares Held In Employee Trust Shares
CommonStockSharesHeldInEmployeeTrustShares
54833
CY2023Q4 us-gaap Common Stock Shares Held In Employee Trust
CommonStockSharesHeldInEmployeeTrust
2100000
CY2022Q4 us-gaap Common Stock Shares Held In Employee Trust Shares
CommonStockSharesHeldInEmployeeTrustShares
63032
CY2022Q4 us-gaap Common Stock Shares Held In Employee Trust
CommonStockSharesHeldInEmployeeTrust
2200000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
272509000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15050000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.11
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
103000
CY2023 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
47000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
272509000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15200000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
221000
CY2021 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
46000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
268550000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15938000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
16.85
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
601000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
891000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
617000
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
73813000
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
114074000
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
576483000
CY2023 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
132969
CY2022 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
232500
CY2021 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
1195529
CY2023 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
555.12
CY2022 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
490.64
CY2021 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
482.20
CY2023Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
300000000.0
CY2021Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
600000000.0
CY2023Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
314100000
CY2023 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2261000
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-3691000
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-987000
CY2023Q4 che Medicare Cap Liability
MedicareCapLiability
13245000
CY2022Q4 che Medicare Cap Liability
MedicareCapLiability
14380000
CY2023Q4 che Retention Bonus
RetentionBonus
8901000
CY2022Q4 che Retention Bonus
RetentionBonus
19634000
CY2023Q4 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
3971000
CY2022Q4 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
2516000
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
23071000
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
24474000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
49188000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
61004000
CY2023 che Percentage Of Individual Amounts Of Total Current Liabilities
PercentageOfIndividualAmountsOfTotalCurrentLiabilities
0.05

Files In Submission

Name View Source Status
0001562762-24-000045-index-headers.html Edgar Link pending
0001562762-24-000045-index.html Edgar Link pending
0001562762-24-000045.txt Edgar Link pending
0001562762-24-000045-xbrl.zip Edgar Link pending
che-20231231.xsd Edgar Link pending
che-20231231x10k.htm Edgar Link pending
che-20231231x10kg001.jpg Edgar Link pending
che-20231231x10kg002.jpg Edgar Link pending
che-20231231xex21.htm Edgar Link pending
che-20231231xex23.htm Edgar Link pending
che-20231231xex24.htm Edgar Link pending
che-20231231xex31_1.htm Edgar Link pending
che-20231231x10k_htm.xml Edgar Link completed
che-20231231xex31_2.htm Edgar Link pending
che-20231231xex32_1.htm Edgar Link pending
che-20231231xex32_2.htm Edgar Link pending
che-20231231xex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
che-20231231_pre.xml Edgar Link unprocessable
che-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
che-20231231_cal.xml Edgar Link unprocessable
che-20231231_def.xml Edgar Link unprocessable